Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended									12 Months Ended
	Dec. 31, 2013		Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 185,003,000	[1]	$ 174,282,000	$ 172,826,000	$ 155,753,000	$ 159,490,000	$ 136,786,000	$ 135,702,000	$ 126,610,000	$ 687,864,000	$ 558,588,000	$ 484,732,000
Cost of revenue	76,339,000	[1]	65,794,000	63,938,000	56,714,000	52,228,000	43,767,000	42,681,000	38,663,000	262,785,000	177,339,000	156,866,000
Total operating expenses	200,865,000	[1]	151,509,000	143,907,000	178,392,000	70,851,000	77,932,000	73,429,000	75,964,000	674,673,000	475,515,000	426,663,000
Net income	1,198,000	[1]	7,793,000	18,094,000	(11,573,000)	20,663,000	9,265,000	13,755,000	7,571,000	15,260,000	51,170,000	127,877,000
Basic (USD per share)	$ 0.02	[1]	$ 0.13	$ 0.33	$ (0.21)	$ 0.39	$ 0.18	$ 0.25	$ 0.14	$ 0.27	$ 0.96	$ 2.39
Diluted (USD per share)	$ 0.02	[1]	$ 0.12	$ 0.30	$ (0.21)	$ 0.38	$ 0.17	$ 0.25	$ 0.14	$ 0.25	$ 0.93	$ 2.35
Legal settlement										0	0	17,984,000
Incline Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Increase in contingent consideration	10,900,000
Decrease in deferred lax liability	13,600,000
Alnylam Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Initial payment	$ 25,000,000				$ 25,000,000					$ 25,000,000

[1] (2)Net income for the fourth quarter of 2013 includes a $10.9 million increase related to the progression in development work for IONSYS related to the Company’s Incline acquisition and a tax benefit of $13.6 million from reducing the Company’s deferred tax liabilities associated with the Incline acquisition.